Go-CHOP for untreated peripheral T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 trial tests how well Go-CHOP works as the first treatment for peripheral T-cell lymphoma (PTCL) subtypes. It aims to see whether adding golidocitinib to standard chemotherapy can control the lymphoma and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your guardian) can sign a consent form before any trial-specific tests or procedures.
- You are 18 years or older, and you can do normal activities (rating 0–2) without getting noticeably worse in the last 2 weeks.
- You have a confirmed PTCL diagnosis from a pathology test, and you have not had anti-lymphoma treatment before (except very short steroid use).
- Your heart function looks strong enough (left heart pumping strength at least 50% on an echocardiogram), and your organs/bone marrow are well enough for treatment.
- You can follow the study plan and attend visits, and you can use reliable birth control during treatment and for the required time after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
This Phase 2 trial compares two chemotherapy approaches—adding lenalidomide to CHOP versus CHOP alone—for people with untreated peripheral T-cell lymphoma (PTCL). The goal is to see if the added medicine improves response and safety.
This trial tests linperlisib (a medicine that targets a cell-growth pathway) together with CHOP chemotherapy in people with peripheral T-cell lymphoma that has not been treated before. It may help shrink the lymphoma and control the disease by combining two approaches.
This trial tests whether adding the targeted drug linperlisib to standard chemotherapy (CHOP) can help adults with certain types of peripheral T-cell lymphoma that haven't been treated yet. It aims to see if the combination works better than CHOP alone.
This trial tests a new oral medication called golidocitinib for people who have just been diagnosed with a specific type of T-cell lymphoma and have not had any prior treatment. The goal is to see if this JAK1 inhibitor can help control the disease.
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.